Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microbiota-targeted alternatives to immunosuppression in IBD during COVID-19
NL-OMON25521Active, not recruiting
- Sponsor
- Nestlé
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of rifaximin in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease (2 arms), sponsored by Nestlé. Started May 2020; status: active, not recruiting.
02
Drugs
rifaximin
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON25521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25521.